• Fosun Pharma annual report for 2025 flagged continued shift toward an innovation-led model, with faster international expansion and wider use of AI across R&D and commercialization.
• Innovation drugs revenue rose 29.6% to RMB 9.9 billion, lifting mix to 23.8% of group revenue.
• Overseas revenue increased 14.9% to RMB 13 billion, taking share of total revenue to 31.3%.
• Pipeline progress included launches for Fu Mai Ning and Fu Tuo Ning in China, with serplulimab gaining European Commission clearance for extensive-stage small cell lung cancer.
• R&D spending totaled RMB 5.9 billion, with 72.8% directed to innovation-drug programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260421-12113399), on April 21, 2026, and is solely responsible for the information contained therein.